PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩100 per share · Prices as of the 2026-10-02 close
SeouLin Bioscience, a life-science reagent and equipment distributor, saw modest annual revenue and operating profit recovery in 2025, but quarterly results continue to swing between profit and loss.
2025 revenue reached KRW 77.09 billion, up slightly year-on-year, but operating margin was only 0.9%
After a KRW 785 million operating profit in Q3 2025, operating losses recurred in Q4 2025 and Q2 2026, showing quarterly instability
The company is diversifying through the POCUS omics analysis brand, a new Bio-Rad distribution deal, and the ecoTree hygiene/disinfection equipment business
The company disclosed a decision to issue KRW 3.335 billion privately placed exchangeable bonds backed by treasury shares
The stock trades below its book value per share, while net income remains far smaller than the 2022 level
Founded in 1984, SeouLin Bioscience is a life-science materials and equipment distributor offering total solutions spanning reagents, equipment, consumables, and technical support.
Reagents account for roughly 62% of revenue, followed by equipment at 20%, consumables at 14%, healthcare devices at 2%, and other items at 2%, underscoring reagent distribution as the core revenue driver.
The company has long served as the official domestic distributor for global brands such as BD Biosciences and Cell Signaling Technology (CST) antibodies, and recently secured domestic distribution rights for Bio-Rad, launching it as a new brand.
In the hygiene and disinfection segment, its ecoTree brand manufactures and sells slightly acidic hypochlorous acid water generators, expanding its footprint into veterinary clinics and other healthcare sites.
Through its AI-based omics brand POCUS, the company added an in-depth blood proteomics analysis service, extending beyond basic-research-stage supply into genomics and proteomics analysis services.
Its customer base spans universities, research institutes, domestic conglomerates and biotech pipelines, and more recently veterinary clinics.
Among domestic peers cited for similar businesses are GC Biopharma Medical Science, Access Bio Korea, and Cosaience, with maintaining agency contracts with overseas principal manufacturers seen as a key competitive factor in this distribution-driven industry.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩16.2B | -₩300M | −2.0% |
| 2025Q3 | ₩22.9B | ₩800M | 3.4% |
| 2025Q4 | ₩20B | ₩100M | 0.7% |
| 2026Q1 | ₩19.5B | ₩200M | 0.9% |
| 2026Q2 | ₩20.8B | -₩600M | −2.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩102.4B | ₩8.6B | ₩9.5B | 8.4% | 11.4% | 53.0% |
| 2023 | ₩89.6B | ₩2.5B | -₩100M | 2.8% | −0.1% | 33.9% |
| 2024 | ₩75.4B | ₩1B | ₩2.9B | 1.3% | 3.5% | 16.9% |
| 2025 | ₩77.1B | ₩700M | ₩700M | 0.9% | 0.9% | 38.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue in 2025 came to KRW 77.09 billion, a slight increase from KRW 75.41 billion in 2024, but still well below the KRW 102.41 billion recorded in 2022.
Operating profit was KRW 692 million in 2025 (0.9% margin), compared with KRW 953 million (1.3%) in 2024, KRW 2.49 billion (2.8%) in 2023, and KRW 8.58 billion (8.4%) in 2022, showing a multi-year margin compression trend.
Net income attributable to owners fell sharply to KRW 732 million in 2025 from KRW 2.91 billion in 2024, after a net loss of KRW 118 million in 2023, reflecting swings across the past four years.
On a quarterly basis, an operating loss of KRW 332 million and a net loss of KRW 56 million in Q2 2025 was followed by a clear improvement in Q3 2025, with revenue of KRW 22.87 billion, operating profit of KRW 785 million, and net income of KRW 767 million.
However, Q4 2025 posted only a marginal operating profit of KRW 142 million alongside a net loss of KRW 356 million, and Q1 2026 delivered a small profit of KRW 175 million in operating income and KRW 163 million in net income, before an operating loss of KRW 597 million recurred in Q2 2026 despite revenue of KRW 20.80 billion, with net income at KRW 342 million.
Over the trailing four quarters (Q3 2025 to Q2 2026), cumulative net income attributable to owners totaled roughly KRW 917 million, indicating a modest but volatile earnings trajectory.
On the cash flow side, operating cash flow turned to a net inflow of KRW 4.76 billion in 2025, an improvement from the net outflow of KRW 4.61 billion in 2024.
The domestic life-science materials and equipment distribution business is directly tied to R&D spending levels at universities, research institutes, and biotech companies.
The fading of pandemic-driven demand has been cited as a key factor behind lower industry-wide revenue bases, as demand for COVID-19-related diagnostic and vaccine product lines has declined.
On the other hand, growth in drug pipelines such as Alzheimer's antibody therapies and obesity/diabetes treatments, along with rising R&D investment in precision medicine and bio big data, are emerging as new demand drivers.
The life-science market is expanding beyond basic-research-stage consumable supply into process development and quality control stages, and demand for equipment, reagents, and consumables is becoming more sophisticated and diversified toward genomics and proteomics analysis.
Within this landscape, SeouLin Bioscience pursues a strategy that combines its distribution channels—leveraging agency status for overseas brands such as BD, CST, and Bio-Rad—with diversification through in-house brands like ecoTree and POCUS.
Competition takes the form of agency and pricing rivalry among similar domestic distributors, with changes in contract terms with principal manufacturers capable of affecting margins.
In April 2026, the company showcased its Bio-Rad precision analysis total solution at 'BIO KOREA 2026,' having earlier presented an integrated bio-analysis service at 'KOREA LAB 2026' in March, as part of efforts to promote new brands and services.
In its hygiene and disinfection business, the company has signed a series of memoranda of understanding with organizations including the Chungbuk Veterinary Medical Association and the Korean Society of Feline Medicine (KSFM), continuing efforts to expand ecoTree equipment adoption in veterinary clinics.
Through a partnership with lens-free digital imaging firm SOL, the company is also pursuing joint development of new businesses in bio materials, parts, and equipment, including digital analyzers, digital diagnostic kits, and digital PCR.
It has additionally signed an implementation agreement with Thermo Fisher Scientific for mass production services of gene delivery vehicle products, opening potential for expanded supply of raw materials related to gene and cell-and-gene therapies.
The company recently disclosed a decision to issue privately placed exchangeable bonds worth KRW 3.335 billion backed by treasury shares, an event worth monitoring in relation to potential changes in outstanding share count or funding purposes.
However, the specific timing and scale at which these new businesses will meaningfully contribute to revenue have not yet been clearly confirmed in disclosures, warranting attention to upcoming quarterly results.
The current share price trades below the company's book value per share, placing it in a discount range relative to net assets. At the same time, with net income sharply reduced from its 2022 profit peak, the price-to-earnings multiple sits at a level higher than during the period when profits were more stable.
This is compounded by the recent pattern of alternating quarterly profits and losses, which complicates interpretation of earnings-based valuation. On dividends, the company has paid cash dividends, though the resulting yield level shifts with the share price and cannot be characterized in absolute terms.
Overall, asset-value and earnings-value signals point in somewhat different directions, suggesting investors may want to weigh both metrics together.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
After an operating loss in Q2 2025, Q3 2025 showed clear improvement with revenue of KRW 22.87 billion and operating profit of KRW 785 million. Q1 2026 also posted simultaneous operating and net profits, bringing cumulative net income attributable to owners over the trailing four quarters to roughly KRW 917 million.
This suggests the company may be passing through a post-pandemic earnings trough toward gradual profit recovery.
The company is diversifying beyond traditional reagent distribution through securing new Bio-Rad brand distribution rights, the POCUS blood proteomics analysis service, and ecoTree hygiene and disinfection equipment.
MOUs targeting veterinary clinics and joint development with SOL on digital diagnostics represent attempts to secure new revenue sources. If these diversification efforts are successfully reflected in revenue, there is room for improved stability in the business structure.
The company holds official domestic distribution status for global life-science brands including BD Biosciences, CST antibodies, and Bio-Rad, providing a stable supply channel.
Its agreement with Thermo Fisher Scientific for mass production services of gene delivery vehicles could also serve as a foundation for expanding supply of gene-therapy-related raw materials. These global partnerships can contribute to acquiring new customers and expanding the product portfolio.
Operating margin declined each year, from 8.4% in 2022 to 2.8% in 2023, 1.3% in 2024, and 0.9% in 2025. Revenue also shrank from KRW 102.4 billion in 2022 to KRW 77.1 billion in 2025, a marked contraction in business scale after the pandemic-driven boom faded.
This multi-year margin and revenue contraction may reflect cost pressures or intensifying price competition inherent to the distribution business.
Operating or net losses recurred across Q2 2025, Q4 2025, and Q2 2026. Whether the profits seen in Q3 2025 and Q1 2026 represent a sustained improvement or a temporary rebound remains to be confirmed through future quarterly results. This volatility reduces the predictability of earnings.
Most of SeouLin's revenue derives from domestic distribution of overseas-manufactured products, making the business dependent on agency margins rather than manufacturing margins of its own. Changes in contract terms with principal manufacturers or entry of competing distributors could directly affect margins. With reagents accounting for 62% of revenue, portfolio diversification remains at an early stage.
With a high proportion of imported reagents and equipment, KRW/USD exchange rate fluctuations can directly affect cost of goods sold and margins. The cost structure is influenced by negotiating power with overseas principal manufacturers on supply prices. A sharp rise in the exchange rate could worsen profitability.
Revenue is tied to R&D budget execution by universities, research institutes, and biotech firms, so a reduction in government R&D budgets or private investment could reduce demand. A decline in demand for COVID-19-related products has been cited as a major factor behind recent earnings weakness. Demand items may shift with changing trends in disease treatment development.
The company disclosed a decision to issue privately placed exchangeable bonds worth KRW 3.335 billion backed by treasury shares. Exercise of the exchange right in the future could lead to changes in outstanding share count or sale of treasury shares, warranting attention as a factor affecting the ownership structure. Additional capital raising, if needed, could affect existing shareholders.
Follow-up disclosures on the privately placed exchangeable bonds (exchange price, exchange period, etc.) should be checked.
The Q3 2026 earnings release should be checked to see whether the profit recovery trend seen from Q3 2025 through Q1 2026 continues.
The extent to which new businesses such as the Bio-Rad brand and POCUS omics service begin contributing to revenue should be checked.
The FY2026 annual business report and audit report should be checked to confirm final annual revenue and profit figures.
SeouLin Bioscience has seen multi-year contraction in revenue and operating margin following the fading of pandemic-era demand, though signs of recovery emerged with profits in Q3 2025 and Q1 2026, only for losses to recur in Q4 2025 and Q2 2026, reflecting ongoing quarterly volatility.
Cumulative net income attributable to owners over the trailing four quarters stood at roughly KRW 917 million, maintaining a modest profit trend but still well below 2022 profit levels.
The company is pursuing diversification beyond traditional reagent and equipment distribution through the new Bio-Rad brand, the POCUS omics service, and ecoTree hygiene and disinfection equipment, which represent potential factors for future revenue structure change, though the timing of their meaningful contribution to earnings has not yet been clearly confirmed in disclosures.
From an asset-value perspective, the share price sits below book value per share, while from an earnings-value perspective, the earnings multiple has risen above levels seen during more stable profit periods due to the recent decline in net income.
Capital-structure events such as the privately placed exchangeable bond issuance and upcoming quarterly earnings releases stand as key points to monitor for gauging future direction.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.